Thursday, September 12, 2013

Ranbaxy - Too Fast Too Furious - Sell Rs.500 plus CALLS and BUY Rs.410 PUTS

Ranbaxy has seen an extraordinary rise from a low of Rs.250 in early August to Rs.460 as of yesterday...The stock appears to be in an exceptionally strong uptrend and the rise is mostly supported by uncertainty/non-clarity around the expected turnaround benefits if the rumors of it being cleared by FDA came true. 

But we believe even if those rumors be true for the time being it seems to more than price the immediate benefits of the same and there is no error of execution built in it. We expect the same to be priced in as risk-reward appear to be fair hereon.Why? 

Check the chart below which shows that EV/EBIDTA is now back to average of the last 5 years. So valuations are no more distressed or cheap.




Even on P/FCF basis the valuations are back to averages. 






However, given the strength of the stock we do recognize that the stock could further surge from here. But its more likely that it could take a breather before surging ahead and given the sharp rise that could be a big swing downwards.

So how to play the stock then?

We advise to SELL CALL OPTIONS at strike price of Rs.500 and above.
Use that money to BUY PUT OPTIONS at strike price of Rs.410

STOP LOSS at cash price of Rs.480...the immediate resistance and next resistance at 510 will be hard to breach

Expect put prices to more than double in the current series...fund the same selling call options...returns will be very high.






Good Luck !!!

Friday, September 6, 2013

Long CIPLA

Long Cipla @ 435 (positional trade call for September series)...

Target - 485....Stop Loss - 428


Cipla has broken out of a long consolidation and we expect the stock to be on a secular uptrend hereon...The company has a new CEO and aggressive growth plans in place. The rupee depreciation is a bonus cherry on the cake. In fact, we expect the stock to double from these levels over the next 3 years. Strong conviction BUY!!

Click on the chart for better view.